Genentech, part of the Roche Group, has reported promising results from its Phase III IMvigor011 trial, evaluating Tecentriq (atezolizumab) as an adjuvant therapy for patients
Genentech announced that the FDA issued a Complete Response Letter regarding its request to expand the use of Columvi, in combination with gemcitabine and oxaliplatin,
Roche announced that Wafaa Mamilli (1967) will join the company as Chief Digital Technology Officer (CDTO), reporting to Group CEO, Thomas Schinecker, and will become a member of
Hippocratic AI, the company that pioneered the first healthcare LLM for patient-facing non-diagnostic clinical tasks, announced that the company completed its series B financing round
